Senior Scientist - R&D

Basecamp Research $140M Series C: key risks and red flags. * Translation fails: EDEN continues to generate impressive in vitro constructs, but lead programs cannot achieve an acceptable in vivo therapeutic index, delivery profile or genomic-safety margin. * The proprietary-data advantage does not compound: additional biodiversity data increases dataset size without producing measurable improvements in prospective therapeutic discovery versus strong public-data or experiment-driven competitors. * Pipeline disclosure stays at platform level: despite $140M of new capital, Basecamp does not nominate a development candidate, disclose a credible IND-enabling path, or provide reproducible prospective validation that connects model outputs to drug-development milestones. One discrepancy merits attention. Basecamp describes broad gene-insertion demonstrations across more than 10,000 disease-related genomic locations, while the public technical work and independent reporting remain fundamentally preclinical evidence, not validation in patients. For diligence, the preprint and experimentally documented scope should carry more weight than promotional descriptions of therapeutic readiness. (EDEN technical preprint, Financial Times coverage) What to watch next: will Basecamp Research lead-asset nomination and ind-enabling progress? Lead-asset nomination or a concrete IND-enabling milestone is the catalyst to watch. The Series C is explicitly intended to move EDEN-designed therapeutics toward clinical development, so disclosure of the first indication, candidate, preclinical package or regulatory timeline would materially reduce the current platform-to-product information gap. (Basecamp Series C announcement) FAQ: Basecamp Research $140M Series C. What exactly changed with Basecamp Research's "$140M Series C" announcement on 23 Sep 2026, and why does it matter? Basecamp raised $140M in an oversubscribed Series C led by S32, with participation from investors including NVIDIA, Anthropic's Anthology Fund, Catalio, NATO Innovation Fund and Rockefeller Foundation. The capital is being directed toward next-generation EDEN models, Basecamp's own therapeutics pipeline and additional pharmaceutical partnerships. (Basecamp Series C announcement, Fierce Biotech coverage) The financing matters because Basecamp is now being funded to demonstrate whether its AI and proprietary biological-data advantage can produce clinical-stage medicines, rather than remaining primarily a discovery platform. What is Basecamp Research's lead therapeutic after the 23 Sep 2026 Series C? Public information does not yet identify a clearly nominated clinical development candidate. Independent reporting describes six programs at or before lead optimization, including in vivo CAR-T programs, a PKU liver gene-therapy program and antimicrobial peptides. (Independent Basecamp pipeline review) That makes candidate nomination, indication selection and IND timing more useful diligence milestones than another model benchmark. Which experiments support the gene-insertion claims referenced around Basecamp Research's 23 Sep 2026 financing? Basecamp's EDEN work reports de novo design of large serine recombinases that can integrate large DNA payloads at specified human genomic sites. The work is available as a bioRxiv preprint, and independent Financial Times coverage reported the January 2026 demonstration involving AI-designed enzymes for large gene insertion. (EDEN technical preprint, Financial Times report) The important limitation is stage: these data support technological feasibility in preclinical systems, not clinical safety or efficacy. What safety questions matter after Basecamp Research's 23 Sep 2026 Series C? For programmable gene insertion, diligence should focus on unintended integration, genomic rearrangements, insertion-site effects, immunogenicity, delivery-related toxicity and durability of the engineered cell state. Basecamp's approach is designed to enable site-specific insertion of large genetic payloads without relying on conventional double-strand-break strategies, but that design objective does not remove the need for extensive in vivo genomic-safety characterization. (EDEN technical preprint) A persuasive development package would therefore need genome-wide specificity data plus therapeutically relevant animal evidence, not only insertion efficiency. How should investors interpret Basecamp Research's approximately $800M valuation after the 23 Sep 2026 financing? Independent reporting places the Series C valuation at about $800M. (Reuters report via Economic Times) The more decision-useful question is what proportion of enterprise value can eventually be supported by proprietary data and platform partnerships versus internally owned therapeutic assets. With the pipeline still preclinical, candidate nomination, pharmaceutical economics and translational milestones remain important missing inputs. Publisher / disclosure. Publisher: LucidQuest Ventures Ltd. Produced: 24 Sep 2026, 09:21 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)-(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided "as is," may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. (C) 2026 LucidQuest Ventures Ltd. Basecamp Research; EDEN; BaseData; aiPGI; programmable gene insertion; large serine recombinases; in vivo cell therapy; in vivo CAR-T; PKU; phenylketonuria; antimicrobial peptides; vaccine target prediction; biological foundation models; biodiversity data; Trillion Gene Atlas; S32; Andy Conrad; NVIDIA; NVentures; Anthropic; Anthology Fund; Catalio Capital Management; NATO Innovation Fund; Rockefeller Foundation; Singular; True Ventures; Richard Pearce; John Finn; David Liu; Broad Institute; University of Oxford; University of Pennsylvania; Claude Science; gene therapy; cell therapy; genome editing; genomic integration; AI drug discovery; preclinical development; IND; CMC; translational medicine; US; UK; Europe Looking for competitive intelligence tailored to your priorities? Contact [email protected] to explore how LucidQuest can support your needs.

NVIDIA, Anthropic, pharma chiefs invest in Basecamp Research. September 24, 2026 One investor, André Hoffmann, Vice-Chairman of Roche, says Basecamp Research's AI-designed therapeutics represent the next stage in the biotech revolution AI-designed therapeutics are a big deal in pharmaceutical investment circles, with Basecamp Research's oversubscribed US$140m Series C financing round offering another clear indication of the momentum building in the space. Venture capital firm S32 led the investment, with backing from major technology and pharmaceutical firms, including NVIDIA and Anthropic through its Anthology Fund. Further participants in the funding round include: Catalio Capital Management, European Tech Collective, Firebrand River Capital, ATO Innovation Fund, Redalpine, The Rockefeller Foundation, Singular and True Ventures. Sovereign AI, the UK's state-backed, AI-focused venture capital fund launched in April 2026, was also involved. Highlighting the widespread interest in the firm, additional investment also came from senior leaders from across pharma, biotech and global industry, including André Hoffmann, Vice-Chairman of Roche, who says: "The biotechnology revolution that began fifty years ago transformed how Healthcare Digital make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. "Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate." S32: at a glance * US$3.5bn - approximate assets under management at S32. * US$517m - raised for S32's sixth flagship fund earlier in 2026. * US$140m - size of Basecamp Research's oversubscribed Series C, led by S32. * Andy Conrad - S32 General Partner and former CEO of Google's Verily, who is joining Basecamp's board. * 2017 - S32 was founded in 2017 by Bill Maris, the former CEO of Google Ventures. The EDEN project. A key focus for the funding will be training the next generation of EDEN models and advancing Basecamp's pipeline of AI-designed therapeutics towards clinical development. Headquartered in London, Basecamp Research is applying its biological foundation model, EDEN, to in vivo cell therapy, with the aim of reprogramming a patient's cells directly inside the body. Existing cell therapies can be highly complex and costly to manufacture, with some treatments costing hundreds of thousands of dollars per patient. The company is combining EDEN's ability to design long, complex DNA sequences with large serine recombinases, which can precisely integrate these sequences into the genome. Basecamp says the approach could enable more sophisticated and personalised cell therapies while simplifying their delivery and manufacture, with potential applications across cancer, autoimmune disease and other conditions. On LinkedIn, following the announcement, Emma Bolton, VP of Global Research at Basecamp, writes: "With this funding, we can focus on our goal of training our EDEN models on evolutionary data from our global biodiversity partnerships and clinical data from our in-house Science team" as the company leverages AI to "accelerate the development of curative medicines for genetic disease." "With this funding, we can focus on our goal of training our EDEN models on evolutionary data from our global biodiversity partnerships and clinical data from our in-house Science team. " Emma BoltonVP of Global Research at Basecamp World-leading training data. Training the EDEN models is a groundbreaking dataset built in collaboration with some of AI's biggest names. At the heart of Basecamp Research's AI platform is the Trillion Gene Atlas, which the company describes as the world's largest proprietary biological AI training dataset. Developed with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas brings together biological data collected through access and benefit-sharing partnerships spanning more than 30 countries and all seven continents. This data is used to train Basecamp's EDEN models to identify patterns across a vast range of previously unseen biology. Rather than focusing on a single scientific application, the models are designed to build a broader understanding of how DNA functions across different forms of life. That foundation enables EDEN to generate potential therapeutic candidates from information about a disease. The approach has already been explored through Basecamp's collaboration with Anthropic on Claude Science, while the models can also be applied to the design of cell and gene therapies, enzymes and peptides. Basecamp Research's key funding partners. CEO: Dario Amodei | HQ: San Francisco, California, US Anthropic is an AI research and safety company developing reliable, interpretable and steerable AI systems, including its Claude family of models. The company works across frontier AI research, product development and AI safety, with applications spanning business, science and healthcare. CEO: Jensen Huang | HQ: Santa Clara, California, US NVIDIA is a technology company specialising in accelerated computing, GPUs and AI infrastructure. Its technologies underpin applications across AI, healthcare, scientific research, robotics and other industries, while its platforms support the development and deployment of increasingly sophisticated AI models. CEO: Dr Thomas Schinecker | HQ: Basel, Switzerland Roche is a global healthcare company combining pharmaceuticals and diagnostics, with a focus on areas including oncology, neurology, cardiovascular and metabolic diseases, immunology and infectious diseases. Founded in Basel in 1896, the company operates across more than 100 countries and treated 39 million patients with its medicines in 2025. Company Portals

Basecamp Research raises $140 million for ai-developed drugs. S32 is leading the oversubscribed Series C round for the AI biotech company. NVIDIA, the NATO Innovation Fund, and Redalpine are also investing. News by Marc Nemitz · London, 24. September 2026 The British-American biotech company Basecamp Research has raised $140 million in an oversubscribed Series C funding round. The round was led by S32. Other investors include NVIDIA, the NATO Innovation Fund, Redalpine, Singular, and True Ventures, among others. Basecamp plans to use the capital to train a new generation of its biological AI models and advance its own pipeline of AI-developed therapeutics toward clinical development. From biological data to new drug candidates. Basecamp Research aims to use AI for more than just individual steps in drug discovery. The company combines its own biological datasets with so-called foundation models and technologies designed to enable the targeted development of DNA sequences for therapeutic applications. At the heart of this effort is the AI model EDEN. It is trained on the so-called Trillion Gene Atlas, which Basecamp describes as the world's largest proprietary biological training dataset for AI. The data comes from collaborations in more than 30 countries across all seven continents. According to the company, partners involved in the project include NVIDIA, Anthropic, PacBio, and Ultima Genomics. Rather than being developed for a single scientific task, the EDEN models are designed to identify overarching biological relationships. Target applications include the development of cell and gene therapies, enzymes, and peptides. Focus shifts to in-house therapy pipeline. The Series C funding round is now specifically intended to accelerate the transition from the technological platform to the company's own therapy candidates. The first step is what is known as in vivo cell therapy. In this approach, cells are genetically modified directly within the patient's body, rather than being extracted first, modified outside the body, and then re-administered. To achieve this, Basecamp combines its EDEN models - designed to develop longer and more complex DNA sequences - with so-called serine recombinases. These are intended to enable precise integration of the sequences into the genome. In the long term, the company sees potential applications in areas such as cancer and autoimmune diseases, among others. Basecamp has already reported positive preclinical results across multiple therapeutic approaches and disease areas. However, the press release does not provide detailed data on these results. Broad investor base for the Series C round. In addition to lead investor S32, participants include Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures. Also participating are executives from the pharmaceutical, biotech, and industrial sectors, including Roche Vice President André Hoffmann. Andy Conrad, general partner at S32 and former CEO of Google's life sciences company Verily, is joining the board of directors of Basecamp Research as part of the funding round. Further pharmaceutical partnerships planned. In parallel with its own pipeline, Basecamp aims to expand its collaboration with pharmaceutical companies. To this end, the company has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer. The combination of proprietary training data and its own AI models is intended to position Basecamp ahead of other companies in the rapidly growing field of AI-driven drug discovery. The company is collaborating with Anthropic, among others. According to Basecamp, the collaboration centered on Claude Science has already demonstrated how EDEN can generate potential therapeutic candidates based on information about a disease. Clinical validation is still pending. With $140 million, Basecamp is securing substantial capital to steer its technology more firmly toward concrete drug development. At the same time, this marks the beginning of a crucial phase for the company. So far, Basecamp has cited preclinical results. Whether therapies designed with EDEN will also prove safe and effective in humans remains to be demonstrated in clinical trials. Furthermore, especially when it comes to interventions in the genome, stringent regulatory and safety requirements are to be expected. The Series C funding thus not only finances further AI training; it is also intended to enable Basecamp to transition from a technological platform for biological AI to a company with its own therapeutic pipeline.